Table 1.
Baseline characteristics of study population
| No cancer (n = 211,373) | Cancer (n = 9,269) | |
|---|---|---|
| Age (years) [mean (SD)] | 42.29 (13.78) | 54.63 (12.19) |
| Sex [n (%)] | ||
| Male | 110,079 (52.08) (52.15) | 4,768 (51.44) (50.82) |
| Female | 101,294 (47.92) | 4,501 (48.56) (49.18) |
| SES [n (%)] | ||
| White collar | 76,076 (35.99) | 3,711 (40.04) |
| Blue collar | 97,298 (46.03) | 4,132 (44.58) |
| Not gainfully employed or missing | 37,999 (17.98) | 1,426 (15.38) |
| Follow-up time (years) [mean (SD)] | 10.68 (2.97) | 8.05 (3.14) |
| Serum Iron (μmol/L) [mean (SD)] | 18.36 (5.91) | 17.96 (5.55) |
| Q1: <14 | 40,647 (19.23) | 1,855 (20.01) |
| Q2: 14–18 | 59,419 (28.11) | 2,718 (29.32) |
| Q3: 18–22 | 56,505 (26.73) | 2,600 (28.05) |
| Q4: ≥22 | 54,803 (25.93) | 2,096 (22.61) |
| Total iron-binding capacity (μmol/L) [mean (SD)] | 60.02 (8.09) | 59.38 (7.74) |
| Q1: <54 | 45,368 (21.46) | 2,121 (22.88) |
| Q2: 54–59 | 50,900 (24.08) | 2,349 (25.34) |
| Q3: 59–65 | 58,540 (27.70) | 2,567 (27.69) |
| Q4: ≥65 | 56,565 (26.76) | 2,232 (24.08) |
| CRP (mg/L) [mean (SD)] | 5.75 (15.85) | 6.77 (22.49) |
| <10 | 183,042 (86.1150) | 7,428 (80.14) |
| ≥10 | 28,331 (13.40) | 1,841 (19.86) |
| History of lung disease [n (%)] | 15,439 (7.30) | 571 (6.16) |